or
forgot password

Measurement of Pro-antiangiogenic Markers in Patients With Hepatic Metastases Undergoing Selective Internal Radiation Therapy (SIRT)


N/A
18 Years
85 Years
Open (Enrolling)
Both
Liver Cancer

Thank you

Trial Information

Measurement of Pro-antiangiogenic Markers in Patients With Hepatic Metastases Undergoing Selective Internal Radiation Therapy (SIRT)


Subjects are invited to participate in this study that have undergone a procedure as their
standard of care. This procedure is known as Selective Internal Radiation Therapy (SIRT), a
procedure designed for the treatment of cancer in the liver. This includes cancer that has
started in the liver as well as cancer that has spread to the liver. The purpose of the
study is to collect blood samples to assess for "biological markers," or substances within
the blood that may promote cancer growth by causing new blood vessels to form. This study
will also use a new method of analyzing medical imaging (CT scan, PET scan) to try and
better understand how cancer in the liver forms new blood vessels. SIRT is standard therapy
and not part of this study. This study involves blood draws only.


Inclusion Criteria:



- Patient has been referred for SIRT as standard of care treatment for hepatocellular
carcinoma or colorectal metastases to the liver and qualify for treatment with SIRT

- Life expectancy of at least 3 months

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Principal Investigator

John L Nosher, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Medicine and Dentistry New Jersey

Authority:

United States: Institutional Review Board

Study ID:

0220080303

NCT ID:

NCT00994370

Start Date:

April 2009

Completion Date:

April 2012

Related Keywords:

  • Liver Cancer
  • Determine the effect of Selective Internal Radiation Therapy on circulating markers of angiogenesis
  • Develop liver lesion signature patterns using standard imaging studies obtained on patients with hepatic malignancy
  • Liver Neoplasms
  • Neoplasm Metastasis

Name

Location
The Cancer Institute of New Jersey New Brunswick, New Jersey  08901
Robert Wood Johnson University Hospital New Brunswick, New Jersey  08903